Lynx1 Capital Management LP - Significant Ownership

Signature - Title
/s/ Weston Nichols - By: Lynx1 Capital Management GP LLC, General Partner, By: Weston Nichols, Sole Member
Location
San Juan, PR
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Lynx1 Capital Management LP.

Significant Ownership of Lynx1 Capital Management LP

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
PASG Passage BIO, Inc. Common Stock, par value $0.0001 per share 19.6% $206K -$2.85M 624K -93.3% LYNX1 CAPITAL MANAGEMENT LP Sep 30, 2025
NEUP Neuphoria Therapeutics Inc. Common Stock, par value $0.00001 per share 16.3% $4.12M 875K 0% Lynx1 Capital Management LP Nov 18, 2025
TCRX TScan Therapeutics, Inc. Voting Common Stock, par value $0.0001 per share 15% $14.1M $4.5M 7.86M +46.7% Lynx1 Capital Management LP Jun 30, 2025
CGEM Cullinan Therapeutics, Inc. Common Stock, par value $0.0001 per share 14.5% $50.7M $24.6M 8.55M +94.3% Lynx1 Capital Management LP Oct 8, 2025
GHRS GH Research PLC Ordinary Shares, nominal value $0.025 per share 13.9% $123M $32.1M 8.6M +35.4% LYNX1 CAPITAL MANAGEMENT LP Sep 30, 2025
DTIL PRECISION BIOSCIENCES INC Common Stock, par value $0.000005 per share 8.8% $5.75M $1.53M 1.04M +36.1% LYNX1 CAPITAL MANAGEMENT LP Sep 30, 2025
ALLO Allogene Therapeutics, Inc. Common Stock, par value $0.001 per share 5.2% $14.9M 10.9M Lynx1 Capital Management LP Dec 31, 2024

Schedules 13D/G Reported by Lynx1 Capital Management LP:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Date Filed
* An asterisk sign (*) next to the price indicates that the price is likely invalid.